Different prognostic effect of postoperative chemoradiation therapy on diploid and nondiploid high-risk rectal cancers

Diseases of the Colon and Rectum

Volumn 41, Issue 12, 1998, Pages 1494-1499

  Tang, Reiping ^a   Ho, Yet Sen ^a   Chen, Hong Hua ^a   See, Lai Chu ^b   Wang, Jeng Yi ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

DNA ploidy; Rectal cancer; Survival rate

Indexed keywords

FLUOROURACIL;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; DIPLOIDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLOIDY; POSTOPERATIVE CARE; PROGNOSIS; RECTUM CANCER; RECTUM RESECTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 0031700036     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02237295     Document Type: Article

References (19)

1. Slanetz CA Jr, Herter FP, Grinnell RS. Anterior resection vs. abdominoperineal resection for cancer of the rectum and rectosigmoid. Am J Surg 1972;123:110-7.
2. Pilipshen SJ, Heilweil M, Quan SH, Sternberg SS, Enker WE. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 1984;53:1354-62.
3. Dixon AR, Maxwell WA, Holmes JT. Carcinoma of the rectum: a 10-year experience. Br J Surg 1991;78:308-11.
4. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465-72.
5. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
6. Lowe SW, Ruley HE, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
7. Fisher DE. Apoptosis in cancer therapy crossing the threshold. Cell 1994;73:539-42.
8. Anthoney DA, McIlwrath AM, Gallagher WM, Edlin AR, Brown R. Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumor cells. Cancer Res 1996;56:1374-81.
9. Remvikos Y, Laurent-Puig P, Salmon RJ, Frelat G, Dutrillaux B, Thomas G. Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int J Cancer 1990;45:450-6.
10. Offerhaus GJ, De Feyter EP, Cornelisse CJ, et al. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 1992;102:1612-9.
11. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;331:231-5.
12. Stal O, Skoog L, Rutqvist LE, et al. S-phase fraction and survival benefit from adjuvant chemotherapy of breast cancer. Br J Cancer 1994;70:1258-62.
13. Karlsson M, Jungnelius U, Aamdal S, et al. Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomized study of disseminated malignant melanoma. Int J Cancer 1996;65:1-5.
14. Hermanek P, Sobin LH, eds. UICC TNM classification of malignant tumors. 4th ed. Berlin: Springer-Verlag, 1987:48-9.
15. Tang R, Ho YS, You YT, et al. Prognostic evaluation of DNA flow cytometric and histopathologic parameters of colorectal cancer. Cancer 1995;76:1724-30.
16. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991;64:192-6.
17. Delattre O, Olschwang S, Law DJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;2:353-6.
18. Meling GI, Lothe RA, Borresen AL, et al. The TP53 tumour suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinicopathologic variables. Br J Cancer 1993;67:93-8.
19. Carder PJ, Cripps KJ, Morris R, et al. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. Br J Cancer 1995;71:215-8.